Literature DB >> 21862209

Phenylketonuria is still a major cause of mental retardation in Tunisia despite the possibility of treatment.

Sameh Khemir1, Monia El Asmi, Haifa Sanhaji, Moncef Feki, Riadh Jemaa, Neji Tebib, Jean Louis Dhondt, Marie Françoise Ben Dridi, Abderraouf Mebazaa, Naziha Kaabachi.   

Abstract

BACKGROUND AND
OBJECTIVE: Accumulation of phenylalanine following a deficiency of phenylalanine hydroxylase activity generates a brain damage with mental retardation: phenylketonuria (PKU). In the developing countries, where PKU systematic neonatal screening program is not established yet, the management of PKU handicap is not properly carried out. The aim of this study was to estimate the frequency of the PKU diagnosed following clinical features anomalies, to provide information about the untreated PKU patients profile in Tunisia not covered by neonatal screening. Also it is stressed that treated patients have a normal development. PATIENTS AND METHODS: This is a retrospective study of 156 cases of PKU detected in Tunisia over 20 years following symptoms suggestive of inherited metabolic disease. Phenylalaninemia level was performed by fluorometric method. Among them 9 patients were treated.
RESULTS: The PKU estimated frequency was 1/7631. The diagnosis mean age was 4 years. The phenylalaninemia mean was 1680 μmol/L; the classical PKU form accounted for 85.3% of cases and the dominant clinical symptoms were: mental retardation (88.2%), motor delays (87.7%), speech difficulties (83.2%) and pigmentation anomalies (61.7%). The treated patients responded to treatment and showed a normal development.
CONCLUSION: The establishment of neonatal screening should be a priority to avoid cases of mentally retardation.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21862209     DOI: 10.1016/j.clineuro.2011.07.016

Source DB:  PubMed          Journal:  Clin Neurol Neurosurg        ISSN: 0303-8467            Impact factor:   1.876


  4 in total

1.  Screening of three Mediterranean phenylketonuria mutations in Tunisian families.

Authors:  Sameh Khemir; Hajer Siala; Sameh Hadj Taieb; Wafa Cherif; Hatem Azzouz; Rym Kéfi; Sonia Abdelhak; Naziha Khouja; Neji Tebib; Taieb Massaoud; Marie Françoise Ben Dridi; Naziha Kaabachi
Journal:  J Genet       Date:  2012       Impact factor: 1.166

2.  Mutations of the phenylalanine hydroxylase gene in patients with phenylketonuria in Shanxi, China.

Authors:  Yong-An Zhou; Yun-Xia Ma; Quan-Bin Zhang; Wei-Hua Gao; Jian-Ping Liu; Jian-Ping Yang; Gai-Xiu Zhang; Xiao-Gang Zhang; Liang Yu
Journal:  Genet Mol Biol       Date:  2012-10-16       Impact factor: 1.771

3.  Phenylketonuria screening and management in southeastern Europe - survey results from 11 countries.

Authors:  Mojca Zerjav Tansek; Urh Groselj; Natalija Angelkova; Dana Anton; Ivo Baric; Maja Djordjevic; Lindita Grimci; Maria Ivanova; Adil Kadam; Vjosa Kotori; Hajrija Maksic; Oana Marginean; Otilia Margineanu; Olivera Miljanovic; Florentina Moldovanu; Mariana Muresan; Michaela Nanu; Mira Samardzic; Vladimir Sarnavka; Aleksei Savov; Maja Stojiljkovic; Biljana Suzic; Radka Tincheva; Husref Tahirovic; Alma Toromanovic; Natalia Usurelu; Tadej Battelino
Journal:  Orphanet J Rare Dis       Date:  2015-05-30       Impact factor: 4.123

4.  Demographic and clinical characteristics of the children with aminoacidopathy in Isfahan Province, Central Iran in 2007-2015.

Authors:  Reza Najafi; Mahin Hashemipour; Omid Yaghini; Fatemeh Najafi; Amirsalar Rashidianfar
Journal:  Indian J Endocrinol Metab       Date:  2016 Sep-Oct
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.